Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
Neurological Center, SMZ Baumgartner Hoehe, Otto-Wagner-Hospital, Vienna, Austria.
J Neurotrauma. 2020 Feb 1;37(3):481-493. doi: 10.1089/neu.2019.6588. Epub 2019 Aug 9.
Epidural spinal cord stimulation (SCS) is currently regarded as a breakthrough procedure for enabling movement after spinal cord injury (SCI), yet one of its original applications was for spinal spasticity. An emergent method that activates similar target neural structures non-invasively is transcutaneous SCS. Its clinical value for spasticity control would depend on inducing carry-over effects, because the surface-electrode-based approach cannot be applied chronically. We evaluated single-session effects of transcutaneous lumbar SCS in 12 individuals with SCI by a test-battery approach, before, immediately after and 2 h after intervention. Stimulation was applied for 30 min at 50 Hz with an intensity sub-threshold for eliciting reflexes in lower extremity muscles. The tests included evaluations of stretch-induced spasticity (Modified Ashworth Scale [MAS] sum score, pendulum test, electromyography-based evaluation of tonic stretch reflexes), clonus, cutaneous-input-evoked spasms, and the timed 10 m walk test. Across participants, the MAS sum score, clonus, and spasms were significantly reduced immediately after SCS, and all spasticity measures were improved 2 h post-intervention, with large effect sizes and including clinically meaningful improvements. The effect on walking speed varied across individuals. We further conducted a single-case multi-session study over 6 weeks to explore the applicability of transcutaneous SCS as a home-based therapy. Self-application of the intervention was successful; weekly evaluations suggested progressively improving therapeutic effects during the active period and carry-over effects for 7 days. Our results suggest that transcutaneous SCS can be a viable non-pharmacological option for managing spasticity, likely working through enhancing pre- and post-synaptic spinal inhibitory mechanisms, and may additionally serve to identify responders to treatments with epidural SCS.
硬膜外脊髓电刺激 (SCS) 目前被认为是一种使脊髓损伤 (SCI) 后恢复运动的突破性方法,但它的最初应用之一是治疗脊髓痉挛。一种新出现的非侵入性激活相似靶神经结构的方法是经皮 SCS。其用于控制痉挛的临床价值将取决于诱导延续效应,因为基于表面电极的方法不能长期应用。我们通过测试组合方法评估了 12 名 SCI 患者单次经皮腰椎 SCS 的效果,分别在干预前、干预即刻和干预后 2 小时进行。刺激以 50Hz 施加 30 分钟,强度低于诱发下肢肌肉反射的阈下强度。测试包括伸展诱发痉挛的评估(改良 Ashworth 量表 [MAS] 总分、摆锤试验、基于肌电图的紧张性牵张反射评估)、阵挛、皮肤传入诱发痉挛,以及 10m 定时步行测试。在所有参与者中,MAS 总分、阵挛和痉挛在 SCS 后即刻显著降低,所有痉挛测量指标在干预后 2 小时均得到改善,具有较大的效应量,包括具有临床意义的改善。对步行速度的影响因人而异。我们进一步进行了为期 6 周的单病例多疗程研究,以探索经皮 SCS 作为家庭治疗的适用性。干预的自我应用是成功的;每周评估表明,在活跃期治疗效果逐渐改善,并持续 7 天产生延续效应。我们的结果表明,经皮 SCS 可能是一种可行的非药物选择,用于治疗痉挛,可能通过增强脊髓前突触和后突触抑制机制起作用,并且可能有助于识别对硬膜外 SCS 治疗有反应的患者。